AIkido Pharma Net Income 2006-2021 | AIKI

AIkido Pharma net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
AIkido Pharma Annual Net Income
(Millions of US $)
2020 $-12
2019 $-4
2018 $2
2017 $-3
2016 $25
2015 $-42
2014 $-31
2013 $-18
2012 $-4
2011 $0
2010 $-8
2009 $-9
2008 $-4
2007 $-1
2006 $4
2005 $-3
AIkido Pharma Quarterly Net Income
(Millions of US $)
2021-06-30 $-1
2021-03-31 $-4
2020-12-31 $0
2020-09-30 $-2
2020-06-30 $-2
2020-03-31 $-8
2019-12-31 $1
2019-09-30 $-3
2019-06-30 $-1
2019-03-31 $-1
2018-12-31 $6
2018-09-30 $-2
2018-06-30 $-0
2018-03-31 $-1
2017-12-31 $-1
2017-09-30 $0
2017-06-30 $-2
2017-03-31 $-1
2016-12-31 $-3
2016-09-30 $-0
2016-06-30 $29
2016-03-31 $-1
2015-12-31 $5
2015-09-30 $-3
2015-06-30 $-40
2015-03-31 $-4
2014-12-31 $-6
2014-09-30 $-5
2014-06-30 $-12
2014-03-31 $-8
2013-12-31 $-4
2013-09-30 $-9
2013-06-30 $-1
2013-03-31 $-4
2012-12-31 $-2
2012-09-30 $-1
2012-06-30 $-0
2012-03-31 $-1
2011-12-31 $2
2011-09-30 $-1
2011-06-30 $-1
2011-03-31 $-0
2010-12-31 $-1
2010-09-30 $-2
2010-06-30 $-3
2010-03-31 $-2
2009-12-31 $-3
2009-09-30 $-2
2009-06-30 $-2
2009-03-31 $-2
2008-12-31 $1
2008-09-30 $-2
2008-06-30 $-1
2008-03-31 $-2
2007-12-31 $-2
2007-09-30 $5
2007-06-30 $-2
2007-03-31 $-2
2006-12-31 $4
2006-09-30 $-0
2006-06-30 $0
2006-03-31 $-1
2005-12-31 $-2
2005-09-30 $0
2005-06-30 $0
2005-03-31 $-1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.077B $0.000B
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. AIkido Pharma Inc., formerly known as Spherix Incorporated, is based in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48